ASH 2024

December 07-10, 2024
San Diego, CA

American Society of Hematology 2024

Explore more Hematology-Oncology congress materials

Results(1)

Hematology-Oncology

A Randomized Comparison of CPX‑351 and FLAG‑Ida in Patients With High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Author(s): Priyanka Mehta Roderick Murphy Saemi Park Nalina Dronamraju Tony Wagner Yana Lutska Stefan Faderl Ian Thomas Joanna Canham Alex Legg

Hematology-Oncology

View Oral Presentation

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.